<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="141261">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01942083</url>
  </required_header>
  <id_info>
    <org_study_id>317-12-001</org_study_id>
    <secondary_id>There is no secondary ID.</secondary_id>
    <nct_id>NCT01942083</nct_id>
  </id_info>
  <brief_title>A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to Investigate Safety and Tolerability of OPB(Otsuka Pharmaceutical Biwa)-111077 in Subjects With Advanced HCC(Hepatocellular Carcinoma)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea Otsuka Pharmaceutical Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea Otsuka Pharmaceutical Co.,Ltd.</source>
  <oversight_info>
    <authority>Korea: Ministry of Food and Drug Safety (MFDS)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, open label, non randomized, multicenter study designed to investigate the
      safety and tolerability of escalating doses of OPB-111077 administered orally, once daily in
      subjects with advanced HCC.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety and tolerability of OPB-111077</measure>
    <time_frame>Within the first cycle [24 days]</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>• Number of participants with Adverse Events as a Measure of Safety and Tolerability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To investigate the maximum tolerated dose (MTD) of OPB-111077</measure>
    <time_frame>Within the first cycle [24 days]</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>• The highest dose that does not lead to discontinuation of dose escalation is defined as the MTD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) properties of OPB-111077 and its metabolites.</measure>
    <time_frame>Within the first cycle [24 days]</time_frame>
    <safety_issue>No</safety_issue>
    <description>The following PK parameters (Cmax (maximum observed concentration), AUC(area uder the concentration time curve from zero), tmax (Time to maximum plasma concentration), etc.) will be determined using a non-compartmental methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response measured by RECIST(Response Evaluation Criteria in Solid Tumor) 1.1</measure>
    <time_frame>Approximately 3-18 weeks depending on tumor response</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessment will be conducted at Screening, end of Cycle 1, end of Cycle 2, end of every 2 cycles thereafter, at the Early Termination (discontinuation) Visit.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Advanced Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>OPB-111077</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>orally, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPB-111077</intervention_name>
    <arm_group_label>OPB-111077</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histopathologically or clinically diagnosed HCC by Korean Liver Cancer Study Group
             (KLCSG) guidelines.

          2. Subject who has advanced HCC

          3. Documented evidence of unresponsiveness to, intolerance to, or ineligibility for
             sorafenib, or unavailability of appropriate sorafenib treatment

          4. Male or female subject, age at consent ≥20 years and ≤75 years.

          5. Life expectancy ≥12 weeks.

          6. Subjects who agree that they or their partner(s) will practice contraception during
             the study period and 3 months (12 weeks) after the completion of study treatment.

          7. Subjects informed of the diagnosis of advanced HCC who are fully informed about the
             content of the study by the Investigator using the written consent form, and give
             written consent to participate in the study of their own free will.

        Exclusion Criteria:

          1. Past liver transplantation

          2. Uncontrollable hepatic encephalopathy or ascites

          3. Presence of brain metastases

          4. Clinically significant gastrointestinal bleeding in past 6 months or current active
             gastrointestinal bleeding.

          5. Primary malignancy other than HCC

          6. Human immunodeficiency virus (HIV) infection

          7. Severe or poorly controlled complication that may affect the conduct or results of
             the study.

          8. Use of Interferon preparation within 4 weeks (28 days) before start of study
             treatment in the present study.

          9. Pregnant, nursing, or possibly pregnant women, or women desiring to become pregnant
             during the study period

         10. Other cases judged by the Investigator to be ineligible for participation in the
             study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>GeumBo Lee</last_name>
    <phone>+82232879252</phone>
    <email>gb122@otsuka.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Seoul &amp; Gyeonggi-Do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 10, 2013</lastchanged_date>
  <firstreceived_date>June 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
